Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review

References

• Martin G, Young M, Aldredge L. Recommendations for initiating systemic therapy in patients with psoriasis. J Clin Aesthet Dermatol. 2019;12(4):13–26.
   PubMedGoogle Scholar
• Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278–285.
   PubMed Web of Science ®Google Scholar
• Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212.
   PubMed Web of Science ®Google Scholar
• Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40.
   PubMed Web of Science ®Google Scholar
• Puig L. Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. Int J Mol Sci. 2017;19(1):58.
   Web of Science ®Google Scholar
• Kane D, Stafford L, Bresnihan B, et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42(12):1460–1468.
   PubMed Web of Science ®Google Scholar
• Tekin HG, Wu JJ, Burge R, et al. Burden and disease characteristics of patients with psoriatic arthritis: a population-based cross-sectional study. J Rheumatol. 2019;46(7):716–720.
   PubMed Web of Science ®Google Scholar
• McKay C, Kondratuk KE, Miller JP, et al. Biologic therapy in psoriasis: navigating the options. Cutis. 2018;102(5S):13–17.
   PubMed Web of Science ®Google Scholar
• American Academy of Dermatology. Psoriasis treatment: apremilast; 2019. Available from: https://www.aad.org/diseases/psoriasis/psoriasis-apremilast.
   Google Scholar
• American Academy of Dermatology. Medication and lights; 2019. Available from: https://www.aad.org/medication-lights.
   Google Scholar
• Fala L. Otezla (Apremilast), an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis. Am Health Drug Benefits. 2015;8(Spec Feature):105–110.
   PubMedGoogle Scholar
• Saini A, Ferguson C, Salkey K. Use of apremilast for aphthous ulcers in a patient with behcet’s syndrome. J Drugs Dermatol. 2018;17(12):1328–1329.
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137–174.
   PubMed Web of Science ®Google Scholar
• Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445–1486.
   Google Scholar
• Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073–1113.
   PubMed Web of Science ®Google Scholar
• Nast A, Spuls PI, Van Der Kraaij G, et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris - update apremilast and secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2017;31(12):1951–1963.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Psoriasis: assessment and management; 2017. Available from: https://www.nice.org.uk/guidance/cg153/chapter/1-Recommendations.
   Google Scholar
• National Institute for Health and Care Excellence. Apremilast for treating moderate to severe plaque psoriasis; 2016. Available from: https://www.nice.org.uk/guidance/ta419.
   Google Scholar
• National Institute for Health and Care Excellence. Apremilast for treating active psoriatic arthritis; 2017. Available from: https://www-nice-org-uk.go.libproxy.wakehealth.edu/guidance/TA433.
   Google Scholar
• Amatore F, Villani AP, Tauber M, et al. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464–483.
   PubMed Web of Science ®Google Scholar
• Kolios AG, Yawalkar N, Anliker M, et al. Swiss S1 guidelines on the systemic treatment of psoriasis vulgaris. Dermatology (Basel). 2016;232(4):385–406.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774–790.
   PubMed Web of Science ®Google Scholar
• Torres T, Puig L. Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2018;19(1):23–32.
   PubMed Web of Science ®Google Scholar
• Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018;9:1048.
   PubMed Web of Science ®Google Scholar
• Keating GM. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2017;77(4):459–472.
   PubMed Web of Science ®Google Scholar
• Haber SL, Hamilton S, Bank M, et al. Apremilast: a novel drug for treatment of psoriasis and psoriatic arthritis. Ann Pharmacother. 2016;50(4):282–290.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Giglio MD, Girolomoni G. Treatment approaches to moderate to severe psoriasis. Int J Mol Sci. 2017;18(11):2427.
   PubMed Web of Science ®Google Scholar
• Crowley JJ, Weinberg JM, Wu JJ, et al. Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol. 2015;151(1):87–94.
   PubMed Web of Science ®Google Scholar
• Canadian Psoriasis Guidelines Addendum C. 2016 Addendum to the Canadian guidelines for the management of plaque psoriasis 2009. J Cutan Med Surg. 2016;20(5):375–431.
   PubMed Web of Science ®Google Scholar
• Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016;74(1):134–142.
   PubMed Web of Science ®Google Scholar
• Excellence NIfHaC. Apremilast for treating moderate to severe plaque psoriasis; 2016. Available from: https://www.nice.org.uk/guidance/ta419.
   Google Scholar
• Shah VV, Lee EB, Reddy S, et al. Comparison of guidelines for the use of TNF inhibitors for psoriasis in the United States, Canada, Europe and the United Kingdom: a critical appraisal and comprehensive review. J Dermatolog Treat. 2018;29(6):586–592.
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850.
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49.
   PubMed Web of Science ®Google Scholar
• Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53.
   PubMed Web of Science ®Google Scholar
• Otezla F. US prescribing information [updated 2014 Mar 03–21]. Available from: http://www.accessdata,fda.gov/drug-satfda_docs/label/2014/205437s0001bl,pdf.
   Google Scholar
• Reddy SP, Lee E, Wu JJ. Apremilast and phototherapy for treatment of psoriasis in a patient with human immunodeficiency virus. Cutis. 2019;103(5):E6–E7.
   PubMed Web of Science ®Google Scholar
• Reddy SP, Shah VV, Wu JJ. Apremilast for a psoriasis patient with HIV and hepatitis C. J Eur Acad Dermatol Venereol. 2017;31(11):e481–e482.
   PubMed Web of Science ®Google Scholar
• Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380(9843):738–746.
   PubMed Web of Science ®Google Scholar
• Papp KA, Kaufmann R, Thaci D, et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol. 2013;27(3):e376–83.
   PubMed Web of Science ®Google Scholar